医薬品とタンパク質との結合に関する物理化学的研究(第8報) : フェノキサゾン化合物と血清アルブミンとの結合

概要

論文の詳細を見る
The combination of 1-hydroxy-5-oxo-5H-pyrido[2,3-a]phenoxazine-3-carboxylic acid (catalin), a phenoxazone compound said to prevent the progress of cataract, with serum albumin in vivo was examined by metachromasis and the redox behavior which is a phenomenon specific to phenoxazone compounds. Theses phenomena were found to be the same, irrespective of the presence or absence of proteins. Therefore, the site in the catalin molecule which takes part in these phenomena is not related to the combination with serum albumin. Amount of combination was calculated from the dialysis equilibrium and the nature of this combination was examined. It was thereby learned that the combination of catalin with serum albumin followed the same mechanism as the combination with crystalline protein reported earlier.
社団法人日本薬学会の論文
1967-09-25